Trial · NCT00991952
Adverse events138
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 138
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Irinotecan Hydrochloride and Alvocidib | 1 | 13 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Irinotecan Hydrochloride | 0 | 6 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Irinotecan Hydrochloride and Alvocidib | 1 | 13 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Irinotecan Hydrochloride | 0 | 6 | 0 |
| other | Alanine aminotransferase increased | Investigations | Irinotecan Hydrochloride and Alvocidib | 3 | 13 | 3 |
| other | Alanine aminotransferase increased | Investigations | Irinotecan Hydrochloride | 1 | 6 | 1 |
| other | Alkaline phosphatase increased | Investigations | Irinotecan Hydrochloride and Alvocidib | 4 | 13 | 4 |
| other | Alkaline phosphatase increased | Investigations | Irinotecan Hydrochloride | 1 | 6 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Irinotecan Hydrochloride and Alvocidib | 9 | 13 | 9 |
| other | Anemia | Blood and lymphatic system disorders | Irinotecan Hydrochloride | 2 | 6 | 2 |
| other | Anorexia | Metabolism and nutrition disorders | Irinotecan Hydrochloride and Alvocidib | 5 | 13 | 5 |
| other | Anorexia | Metabolism and nutrition disorders | Irinotecan Hydrochloride | 3 | 6 | 3 |
| other | Aspartate aminotransferase | Investigations | Irinotecan Hydrochloride and Alvocidib | 4 | 13 | 4 |
| other | Aspartate aminotransferase | Investigations | Irinotecan Hydrochloride | 0 | 6 | 0 |
| other | Blood bilirubin increased | Investigations | Irinotecan Hydrochloride and Alvocidib | 2 | 13 | 2 |
| other | Blood bilirubin increased | Investigations | Irinotecan Hydrochloride | 0 | 6 | 0 |
| other | Constipation | Gastrointestinal disorders | Irinotecan Hydrochloride and Alvocidib | 2 | 13 | 2 |
| other | Constipation | Gastrointestinal disorders | Irinotecan Hydrochloride | 1 | 6 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Irinotecan Hydrochloride and Alvocidib | 1 | 13 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Irinotecan Hydrochloride | 1 | 6 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00991952/events